US FDA Issues Final Guidance On Cybersecurity In Medical Devices

Maryland: The FDA has issued the final guidance Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket SubmissionsThe guidance replaces Content of Premarket Submissions for Management of Cybersecurity in Medical Devices, issued on October 2, 2014.

This document provides recommendations on medical device cybersecurity considerations, device design and labeling, and what information to include in premarket submissions. “These recommendations are intended to promote consistency, facilitate efficient premarket review and help ensure that marketed medical devices are sufficiently resilient to cybersecurity threats,” the FDA states.

The guidance emphasizes that cybersecurity is part of device safety and the quality system requirements found in 21 CFR Part 820, which may be relevant at the premarket stage, postmarket stage or both. It provides recommendations on:

 

  • How connected devices should be tested and validated against breaches that affect multiple connected devices.
  • Provides labeling recommendations for devices with cybersecurity risks.
  • Recommends that companies develop cybersecurity management plans that communicate how they will identify and communicate postmarket vulnerabilities in accordance with 21 CFR 820.100.
  • Recommends that manufacturers provide an updateability and patchability view that describes the end-to-end process that permits software updates and patches to be provided/deployed once the device is in the field.

The guidance recommends that manufacturers use device design processes such as those described in the QS regulation to support secure product development and maintenance. But, to preserve flexibility, they may use other existing frameworks that satisfy the QS regulation and align with FDA’s recommendations for using a Security Product Development Framework (SPDF). Possible frameworks to consider include, but are not limited to, the medical device-specific framework that can be found in the Medical Device and Health IT Joint Security Plan (JSP) 30 and IEC 81001-5-1 or in ANSI/ISA 62443-4-1 Security for industrial automation and control systems Part 4- 1: Product security development life-cycle requirements.

Related Posts

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

New Delhi: Serious legal gaps in the Drugs and Cosmetics Act, 1940, combined with acute shortages of manpower and infrastructure, continue to impede the Central Drugs Standard Control Organisation (CDSCO)…

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna: In a significant ruling that could have far-reaching implications for NDPS drug-related prosecutions involving common pharmaceutical compounds, the Patna High Court has held that Phenothiazine and Promethazine do not…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines